Results 321 to 330 of about 6,357,066 (352)

MEL

2003
Publisher Summary The Maya Embedded Language (MEL) is Maya's most easily accessible programming interface. Selecting an object or displaying a dialog box is the direct result of a MEL command being executed. In fact, the entire Maya graphical user interface (GUI) is controlled by MEL. Almost all of Maya's functionality can be accessed through MEL. MEL
openaire   +2 more sources

Mel W, a new trypanosomicidal agent derived from Mel B

Transactions of the Royal Society of Tropical Medicine and Hygiene, 1959
Mel W, a water soluble derivative of Mel B, has been tested in eight cases of first and second stage T. gambiense sleeping sickness. The immediate therapeutic results observed call for an extended study of Mel W, which appears to have significant advantages over Mel B.
Ernst A.H. Friedheim, R. T. De Jongh
openaire   +3 more sources

Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80

, 2016
10009Background: Little is known about the use of checkpoint blockade in pts aged 80+. Here we report the efficacy and safety of these agents in this pt population.
C. Friedman, Troy Z. Horvat, J. Minehart, K. Panageas, M. Callahan, P. Chapman, Parisa Momtaz, M. Postow, A. Shoushtari, J. Wolchok, S. Lichtman   +10 more
semanticscholar   +1 more source

Heart Sound Classification Using Deep Learning Techniques Based on Log-mel Spectrogram

Circuits, systems, and signal processing, 2022
M. Nguyen, W. Lin, J. Huang
semanticscholar   +1 more source

Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.

, 2015
9018 Background: NIVO is a programmed death-1 (PD-1) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in pts with MEL.
J. Weber, S. Antonia, S. Topalian, D. Schadendorf, J. Larkin, M. Sznol, Helen Liu, I. Waxman, C. Robert   +8 more
semanticscholar   +1 more source

Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.

, 2015
9005 Background: The anti–PD-1 antibody pembro is approved in the US for treating unresectable or metastatic MEL that progressed following ipilimumab (IPI) and, if BRAF V600 mutant, a BRAF inhibito...
A. Daud, A. Ribas, C. Robert, F. Hodi, J. Wolchok, A. Joshua, W. Hwu, J. Weber, T. Gangadhar, R. Joseph, R. Dronca, A. Patnaik, H. Zarour, R. Kefford, Jill A. Lindia, Xiaoyun Li, S. Ebbinghaus, S. P. Kang, O. Hamid   +18 more
semanticscholar   +1 more source

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

Journal of Clinical Oncology, 2014
LBA9000^ Background: The humanized monoclonal IgG4 anti-PD-1 antibody MK-3475 has demonstrated durable antitumor activity in MEL and NSCLC. We evaluated MK-3475 efficacy and safety in a pooled analysis of 411 MEL pts.
A. Ribas, F. Hodi, R. Kefford, O. Hamid, A. Daud, J. Wolchok, W. Hwu, T. Gangadhar, A. Patnaik, A. Joshua, P. Hersey, J. Weber, R. Dronca, H. Zarour, K. Gergich, Xiaoyun Li, R. Iannone, S. P. Kang, S. Ebbinghaus, C. Robert   +19 more
semanticscholar   +1 more source

The Revelations of Mel

The American Indian Quarterly, 2007
By coincidence, in a conversation earlier this year I was arguing that the 197os descendants of John Wayne's swagger and renegade manner in The Searchers were either Clint Eastwood or Charles Bronson, but that in the 198os, instead of someone like Harrison Ford (whose characters, especially Indiana Jones, often register signs of humility) and amongst ...
openaire   +2 more sources

Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors.

Science, 1989
The neutrophil Mac-1 and gp100MEL-14 adhesion proteins are involved in neutrophil extravasation during inflammation. Both the expression and activity of Mac-1 are greatly increased after neutrophil activation.
T. Kishimoto, M. Jutila, E. Berg, E. Butcher   +3 more
semanticscholar   +1 more source

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

Journal of Clinical Oncology, 2014
LBA9003^ Background: We report updated survival and clinical activity in initially enrolled cohorts and activity by BRAF MT status in a phase I trial of concurrent and sequenced NIVO + IPI.
H. Kluger, M. Callahan, M. Postow, R. Gordon, N. Segal, N. Rizvi, A. Lesokhin, M. Atkins, J. Kirkwood, M. Burke, A. Ralabate, A. Rivera, S. Kronenberg, B. Agunwamba, W. Feely, Q. Hong, S. Krishnan, A. Gupta, J. Wolchok   +18 more
semanticscholar   +1 more source